Efficacy and safety of quinapril 40mg once daily as monotherapy for patients with poorly controlled hypertension: The EUREKA study

Clinical Drug Investigation

Volumn 20, Issue 2, 2000, Pages 81-88

  Pueyo, Carol ^a   Diaz, C ^a   Sol, J M ^a   Masramon, X ^a   Hernandez G ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; QUINAPRIL;

ABDOMINAL PAIN; ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033864642     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020020-00002     Document Type: Article

References (21)

1. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
3. Evolucion del control de la hipertension arterial en Espana. Resultados del Estudio Controlpres 98
4. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: A review of potential benefits and possible adverse reactions
5. The impact of angiotensin-converting enzyme inhibitors on the arterial wall
6. Angiotensin-converting enzyme inhibitors
7. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue
8. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors [published erratum appears in J Hypertens Suppl 1991 Jun; 9 (6):following H30]
9. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats
10. The safety and tolerability of quinapril
11. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders
12. Multicentric study of quinapril, an angiotensin converting enzyme inhibitor, in the treatment of mild to moderate essential hypertension
13. Reducing the burden of diabetes: Managing cardiovascular disease
14. Quinapril reduces arterial blood pressure and improves metabolic control in elderly hypertensive diabetic patients
15. The treatment of moderate to severe hypertension with ACE inhibitors
16. Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril
17. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients
18. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: Results from a population-based study in the elderly
19. The safety profile of quinapril: Is there a difference among ACE inhibitors?
20. Overall tolerance and safety of quinapril in clinical trials
21. The safety of ACE inhibitors for the treatment of hypertension and congestive heart failure